Meglitinides are oral type 2 diabetes pills that stimulate brief insulin release at mealtime. The class includes repaglinide and nateglinide. They lower A1C by 0.5 to 1.5 percent with less prolonged hypoglycemia than sulfonylureas and allow meal-skipping. Today they are niche agents — useful for irregular eaters, mild kidney disease, or when newer drugs are not accessible.
What Meglitinides Are
Meglitinides — sometimes called “glinides” or “prandial insulin secretagogues” — are a class of non-sulfonylurea insulin secretagogues developed in the 1990s. The class name comes from the chemical moiety in repaglinide; nateglinide is structurally different (a D-phenylalanine derivative) but functionally similar.
The two FDA-approved members in the United States:
- Repaglinide (Prandin) — approved 1997
- Nateglinide (Starlix) — approved 2000
Both are now available as generics. A third agent, mitiglinide, is approved in Japan but not in the US.
How Meglitinides Work
Pancreatic beta cells have ATP-sensitive potassium (K-ATP) channels on their plasma membrane. When glucose enters the cell and is metabolized, ATP rises, closing K-ATP channels. Channel closure depolarizes the cell, opens voltage-gated calcium channels, and triggers insulin granule release.
Meglitinides bind directly to the SUR1 regulatory subunit of the K-ATP channel, closing the channel and triggering insulin secretion. They bind a different site from sulfonylureas but use the same downstream pathway. The key pharmacologic difference is binding kinetics: meglitinides associate and dissociate much faster than sulfonylureas, producing a brief insulin release rather than a sustained elevation.
| Property | Meglitinides | Sulfonylureas |
|---|---|---|
| Onset | 15-30 min | 30-60 min |
| Peak | 1 hour | 1-3 hours |
| Duration | 4-6 hours | 10-24 hours |
| Insulin release pattern | Brief, mealtime-matched | Sustained, all-day |
| Hypoglycemia profile | Mealtime if not eaten; less prolonged | Can persist for many hours |
Who Qualifies
Meglitinides are indicated for adults with type 2 diabetes, as monotherapy or in combination with metformin or thiazolidinediones. They are not used in type 1 diabetes or diabetic ketoacidosis. They are typically considered when:
- Post-meal glucose drives most of the elevated A1C
- Sulfonylurea hypoglycemia has been a problem
- Meal patterns are irregular (shift work, intermittent fasting, frequent travel)
- Mild to moderate kidney disease makes sulfonylureas high-risk (repaglinide especially)
- Sulfa allergy
- Newer agents (GLP-1 RA, SGLT2i, DPP-4i) are not accessible
Expected Effects
| Outcome | Repaglinide | Nateglinide |
|---|---|---|
| A1C reduction (monotherapy) | 1.0-1.5% | 0.5-1.0% |
| A1C reduction (added to metformin) | 0.5-1.0% additional | 0.3-0.6% additional |
| Fasting glucose reduction | 30-50 mg/dL | 10-20 mg/dL |
| 2-hour post-meal glucose reduction | 50-90 mg/dL | 40-70 mg/dL |
| Weight effect | +1-3 kg | +1-2 kg |
Common Side Effects
The two meglitinides share a similar side-effect profile:
- Hypoglycemia — more frequent with repaglinide than nateglinide; both less than sulfonylureas
- Upper respiratory infection (especially in trials — likely partly background rate)
- Headache
- Sinusitis
- Diarrhea or constipation
- Joint pain
- Modest weight gain
- Rare hypersensitivity reactions
Drug Interactions
The most clinically important interaction is repaglinide plus gemfibrozil — gemfibrozil inhibits CYP2C8 and raises repaglinide levels about 10-fold, with prolonged hypoglycemia. This combination is contraindicated.
Other interactions:
- Clopidogrel (CYP2C8 inhibition) — significant rise in repaglinide
- Itraconazole, ketoconazole, clarithromycin — raise repaglinide via CYP3A4
- Rifampin, carbamazepine, phenytoin — lower repaglinide via CYP induction
- Beta-blockers — mask hypoglycemia symptoms
- NSAIDs, salicylates, MAOIs, alcohol — enhance hypoglycemic effect
Nateglinide has fewer drug interactions because it is metabolized through multiple pathways.
Contraindications
- Type 1 diabetes
- Diabetic ketoacidosis
- Concomitant gemfibrozil (repaglinide specifically)
- Known hypersensitivity
- Pregnancy (insulin preferred)
Comparison Table
| Feature | Repaglinide | Nateglinide | Glipizide (SU) |
|---|---|---|---|
| Class | Meglitinide | Meglitinide | Sulfonylurea |
| Approved | 1997 | 2000 | 1984 |
| Onset | 15-30 min | 15 min | 30-60 min |
| Duration | 4-6 hr | 4 hr | 12-24 hr |
| A1C reduction | 1.0-1.5% | 0.5-1.0% | 1.0-2.0% |
| Hypoglycemia risk | Moderate | Low-Moderate | High |
| Weight gain | +1-3 kg | +1-2 kg | +2-3 kg |
| Dosing frequency | 3x daily | 3x daily | 1-2x daily |
| Renal use | Good (CKD-friendly) | OK | Caution in CKD |
| Gemfibrozil interaction | Contraindicated | None | None |
Place in Modern Therapy
The 2024 ADA Standards of Care recommend metformin as foundational therapy for most adults with type 2 diabetes, with second-line preference for GLP-1 receptor agonists or SGLT2 inhibitors based on individual cardiovascular, renal, and weight considerations. DPP-4 inhibitors and basal insulin follow. Sulfonylureas and meglitinides appear as cost-conscious options when newer agents are not feasible.
Practical scenarios where a meglitinide makes sense in 2024:
- Patient with irregular meal schedule (shift work, intermittent fasting protocols, prolonged or unpredictable fasting)
- Patient with eGFR 30 to 60 mL/min where glyburide or glimepiride hypoglycemia would be unsafe (repaglinide preferred)
- Patient with documented sulfa allergy where sulfonylureas are avoided
- Patient who cannot afford brand-name DPP-4i, SGLT2i, or GLP-1 RA, and who has had hypoglycemia on a sulfonylurea
- Patient on metformin who needs additional A1C lowering and prefers oral therapy over injection
The NAVIGATOR Trial and Prediabetes
The NAVIGATOR trial randomized over 9,000 patients with impaired glucose tolerance and cardiovascular risk to nateglinide, valsartan, both, or placebo. Nateglinide did not reduce progression to type 2 diabetes (36 percent vs 34 percent for placebo) and did not reduce cardiovascular outcomes. This negative result, along with the lack of prevention data for repaglinide, means meglitinides are not used for diabetes prevention in prediabetes — that role belongs to lifestyle change, metformin (DPP/DPPOS), and emerging GLP-1 evidence.
Practical Considerations
- Take 15 to 30 minutes before each meal.
- Skip the dose if you skip the meal; add a dose if you add a meal.
- Carry a glucose source for occasional hypoglycemia.
- Check post-meal glucose to assess response.
- Review medication list for gemfibrozil and other interactions before starting repaglinide.
- Both meglitinides are generic and reasonably affordable.
Related Reading
For deeper detail, see our pieces on repaglinide and nateglinide. Also see our pillar on treatment options and our explanation of A1C levels.
The Bottom Line
Meglitinides are short-acting oral insulin secretagogues taken before each meal in type 2 diabetes. The class includes repaglinide and nateglinide. They lower A1C by 0.5 to 1.5 percent, cause less prolonged hypoglycemia than sulfonylureas, and allow meal-skipping. Today they are niche agents, displaced from first-line by metformin and the newer GLP-1, SGLT2, and DPP-4 classes. Their best uses remain irregular eaters, mild-to-moderate kidney disease, sulfa allergy, and cost-constrained situations. Talk to your doctor about whether a meglitinide fits your eating pattern, kidney function, and overall diabetes plan.
